Global Reach


Health Decisions provides sponsors with Global Agility, flexible global reach enabling them to conduct a global study in the most favorable locations without incurring overhead costs from nonparticipating regions and sites. We provide Global Agility through a combination of data-driven central management from the US with the regional experience, expertise and insight of carefully selected resources in each country or region. Primary project management and lines of communication from Health Decisions’ global headquarters in the US keep the sponsor current on the study as a whole and all sites regardless of location. Health Decisions provides sponsors with access to 75 countries served by more than 50 offices and 1,500 staff through the Agile Global Alliance.
HD Global Map V5

Global Agility and Reach with LiveData from LiveTrial CTMS

Health Decisions LiveTrial Global CTMS provides sponsors with a LiveData window on each study. You see what we see when we see it—continuous, detailed and comprehensive performance indices and analytics for each site. We select global teams for each project based not only on the advantages of the their location, but also their expertise in everything that matters to the success of the sponsor’s study. The result is unrivaled flexibility, oversight and control over global studies.

Global Success

Health Decisions achieves extraordinary results for sponsors worldwide in a variety of therapeutic areas and indications:

Therapeutic Area:

Metastatic Breast Cancer

Patients:

460

Sites:

95

Countries:

Canada, Russia, UK, US

Outcome:

Trial completed one year ahead of expected; resulted in $366M in unplanned revenue to sponsor

Therapeutic Area:

Peripheral Arterial Occlusion

Patients:

120

Sites:

36

Countries:

Hungary, Russia, South Africa, UK, US

Outcome:

Big 5 pharma outlicensed because enrollment considered unfeasible; Enrolled faster than most optimistic projections

Therapeutic Area:

Alzheimer’s

Patients:

1500

Sites:

107

Countries:

Australia, Ca, France, SA, UK, US

Outcome:

Saved $32M for the sponsor of $110M study by cutting 1.5 years off 5-year timeline